Literature DB >> 21545484

Should monitoring of vancomycin be delayed? A case of likely nephrotoxicity occasioned by morbid obesity and minimal monitoring.

Terry E Jones1, Hayley Vasileff, Cassie Hewton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 21545484      PMCID： PMC3522820          DOI： 10.1111/j.1365-2125.2011.04006.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

Review 1.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

2.  Aminoglycoside clearance is a good estimate of creatinine clearance in intensive care unit patients.

Authors:  T E Jones; J V Peter; J Field
Journal:  Anaesth Intensive Care       Date:  2009-11       Impact factor: 1.669

3.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists.

Authors:  Jennifer H Martin; Ross Norris; Michael Barras; Jason Roberts; Ray Morris; Matthew Doogue; Graham R D Jones
Journal:  Clin Biochem Rev       Date:  2010-02

4.  Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire.

Authors:  C M Tobin; J M Darville; A H Thomson; G Sweeney; J F Wilson; A P MacGowan; L O White
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

Review 5.  Contrast-induced nephropathy: definition, epidemiology, and patients at risk.

Authors:  R Mehran; E Nikolsky
Journal:  Kidney Int Suppl       Date:  2006-04       Impact factor: 10.545

Review 6.  Selection of contrast media.

Authors:  R Solomon; C Briguori; C Biguori; M Bettmann
Journal:  Kidney Int Suppl       Date:  2006-04       Impact factor: 10.545

7.  Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.

Authors:  K Vance-Bryan; D R Guay; S S Gilliland; K A Rodvold; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

8.  Vancomycin pharmacokinetics in normal and morbidly obese subjects.

Authors:  R A Blouin; L A Bauer; D D Miller; K E Record; W O Griffen
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

9.  Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.

Authors:  Thomas P Lodise; Ben Lomaestro; Jeffrey Graves; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

10.  Vancomycin therapy in patients with impaired renal function: a nomogram for dosage.

Authors:  R C Moellering; D J Krogstad; D J Greenblatt
Journal:  Ann Intern Med       Date:  1981-03       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.